Brooke McCormick

At SABCS 2025, Amrita Basu, PhD, underscores that effective AI use for breast cancer care depends on human oversight.

Photopsia associated with camizestrant was mostly mild, nondisabling, and reversible, according to Adam Brufsky, MD, PhD, at SABCS 2025.

While DTC pharmacy models offer convenience, they may create cost, access, and guidance barriers for the "working poor."

SABCS 2025 will spotlight new advances in breast cancer research while offering networking opportunities to foster connections among attendees.

Experts explain that DTC models could improve medication adherence through convenience and incentives, but higher costs may limit their effectiveness.

Hereditary ovarian cancer genes occur across diverse populations, supporting inclusive genetic testing.

As the first immunotherapy option in this setting, the approval sets a new standard for resectable early-stage gastric and gastroesophageal junction (GEJ) cancers.

Jennifer Graff, PharmD, and Brian Reid, MS, emphasize that DTC pharmacy models can give patients more convenient access to medications but may increase out-of-pocket costs.

Over 50% of patients with high-grade serous ovarian cancer (HGSOC) had surgery, often decades before diagnosis, where salpingectomy could have reduced risk.

Mirvetuximab soravtansine, particularly in combination regimens, showed promising efficacy and an acceptable safety profile in recurrent ovarian cancer.

The expansion of direct-to-consumer (DTC) pharmaceutical manufacturer models and the upcoming TrumpRx launch offer lower costs but create new complexities for patients.

Secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves overall survival in platinum-sensitive recurrent ovarian cancer.

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.

US adults with arthritis have higher odds of stress, urge, and mixed urinary incontinence, highlighting the need for routine screening and integrated care.

The 2024-2025 US influenza season hit older adults hardest, driving hospitalizations and costs, while vaccine coverage remained below targets.

RSV vaccines protect adults 60 years and older against illness, but effectiveness declines over 2 seasons, especially in those who are immunocompromised.

Discontinuing GLP-1 use before or early in pregnancy raises gestational weight gain, birth weight percentile, and the risk of pregnancy complications.

Most US patients eligible for hepatitis B virus (HBV) treatment remain untreated, raising risks of liver disease and complications.

Patients hospitalized for bronchiectasis exacerbations face higher mortality, longer stays, and greater costs than those with COPD or asthma.

Long-term nitrogen dioxide exposure raises ovarian cancer risk, underscoring the need for stricter air quality measures.

Rachel A. Prusynski, DPT, PhD, discusses her study on how payment models affect home health care delivery and patient outcomes.

Targeted financing, clinician recruitment, and telehealth expansion are needed to improve rural primary care.

Infectious disease was hit hardest by funding cuts to NIH grant for clinical trials that did not align with the Trump administration's priorities.

Early measles vaccination among Texas infants surged in early 2025, likely helping reduce their risk amid the nation's largest outbreak since 2000.

Global ovarian and uterine cancer cases due to high BMI have risen sharply over the past 30 years, especially in low- to middle-income sociodemoraphic regions.

Cefdinir is linked to nearly double the outpatient uncomplicated UTI treatment failure of cephalexin, with higher recurrence and increased resistance to other cephalosporins.

Brensocatib improves lung structure and reduces exacerbations in non-cystic fibrosis bronchiectasis with or without COPD, according to posters presented at this year's CHEST meeting.

Aligning patient and insurer incentives through price transparency, lower out-of-pocket costs, and broader networks could boost ASC use and access.

Oncology experts at PCOC 2025 discuss breakthrough therapies, AI-driven care, and evolving care delivery models shaping the future of oncology.

Patients save most on outpatient surgeries at in-network sites, so Xiaoxi Zhao, PhD, emphasizes that transparency could help them make better cost choices.